Goldman Sachs’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-322,060
| Closed | -$3.09M | – | 5346 |
|
|
2024
Q4 | $3.09M | Sell |
322,060
-285,298
| -47% | -$2.74M | ﹤0.01% | 3208 |
|
|
2024
Q3 | $1.74M | Buy |
607,358
+105,498
| +21% | +$302K | ﹤0.01% | 3459 |
|
|
2024
Q2 | $1.47M | Buy |
501,860
+51,343
| +11% | +$150K | ﹤0.01% | 3384 |
|
|
2024
Q1 | $1.44M | Sell |
450,517
-20,455
| -4% | -$65.3K | ﹤0.01% | 3390 |
|
|
2023
Q4 | $1.58M | Buy |
470,972
+3,871
| +0.8% | +$13K | ﹤0.01% | 3359 |
|
|
2023
Q3 | $1.11M | Buy |
467,101
+217,509
| +87% | +$518K | ﹤0.01% | 3469 |
|
|
2023
Q2 | $439K | Sell |
249,592
-43,770
| -15% | -$77K | ﹤0.01% | 4042 |
|
|
2023
Q1 | $904K | Buy |
293,362
+164,649
| +128% | +$507K | ﹤0.01% | 3724 |
|
|
2022
Q4 | $682K | Buy |
128,713
+54,569
| +74% | +$289K | ﹤0.01% | 3911 |
|
|
2022
Q3 | $262K | Buy |
74,144
+29,429
| +66% | +$104K | ﹤0.01% | 4606 |
|
|
2022
Q2 | $116K | Sell |
44,715
-11,762
| -21% | -$30.5K | ﹤0.01% | 5071 |
|
|
2022
Q1 | $253K | Sell |
56,477
-21,455
| -28% | -$96.1K | ﹤0.01% | 4968 |
|
|
2021
Q4 | $531K | Buy |
77,932
+20,757
| +36% | +$141K | ﹤0.01% | 4475 |
|
|
2021
Q3 | $416K | Buy |
57,175
+22,718
| +66% | +$165K | ﹤0.01% | 4488 |
|
|
2021
Q2 | $345K | Sell |
34,457
-4,792
| -12% | -$48K | ﹤0.01% | 4628 |
|
|
2021
Q1 | $375K | Sell |
39,249
-2,776
| -7% | -$26.5K | ﹤0.01% | 4527 |
|
|
2020
Q4 | $461K | Buy |
42,025
+5,753
| +16% | +$63.1K | ﹤0.01% | 3868 |
|
|
2020
Q3 | $322K | Buy |
+36,272
| New | +$322K | ﹤0.01% | 3869 |
|